文献速递儿童血液肿瘤与免疫

儿童B-ALL二代测序基因突变谱及其对微小残留病的影响

[Genomics of next generation sequencing in pediatric B-acute lymphoblastic leukemia and its impact on minimal residual disease].
PubMed 文献 · Zhonghua Er Ke Za Zhi · 2023-01-01

该回顾性队列纳入506例初诊B-ALL患儿,按化疗第19天MRD≥1.00%或<1.00%、第46天MRD≥0.01%或<0.01%分组比较基因突变谱。96.2%患儿检出基因突变,以KRAS和NRAS最常见;PTPN11、KMT2A、BCORL1、JAK2、JAK3突变及年龄>10岁为MRD独立危险因素,TEL-AML1和BCR-ABL1融合基因为保护因素。

要点

  • 初诊B-ALL患儿基因突变检出率高,RAS信号通路KRAS/NRAS突变最常见。
  • PTPN11、KMT2A突变及年龄>10岁与第19天MRD≥1.00%风险升高独立相关。
  • BCORL1、JAK2、JAK3突变与第46天MRD≥0.01%风险升高独立相关。

核心结论

  • 儿童B-ALL易发生基因突变,以RAS信号通路异常最常见。
  • 信号转导相关PTPN11、JAK2、JAK3基因突变,表观遗传相关KMT2A基因突变,转录因子相关BCORL1基因突变是MRD的独立危险因素。

研究设计与样本

  • 回顾性队列研究,纳入2018年9月至2021年7月中国医学科学院血液病医院诊治的506例初诊B-ALL患儿。
  • 依据化疗第19天MRD结果分为≥1.00%组(114例)和<1.00%组(392例),依据第46天MRD结果分为≥0.01%组(76例)和<0.01%组(430例)。
  • 组间比较采用χ2检验或Fisher确切概率法,采用Logistic回归分析第19天和第46天MRD的独立影响因素。

主要发现

  • 506例患儿中男318例、女188例;487例(96.2%)检测到共187种基因突变。
  • 最常见突变为信号转导相关KRAS基因(111例,22.8%)和NRAS基因(99例,20.3%)。
  • 第19天MRD≥1.00%的独立影响因素包括PTPN11突变(OR=1.92,95%CI 1.00~3.63)、KMT2A突变(OR=3.51,95%CI 1.07~11.50)、TEL-AML1融合基因(OR=0.48,95%CI 0.27~0.87)、BCR-ABL1融合基因(OR=0.27,95%CI 0.08~0.92)及年龄>10岁(OR=1.91,95%CI 1.12~3.24)。
  • 第46天MRD≥0.01%的独立影响因素包括BCORL1突变(OR=2.96,95%CI 1.18~7.44)、JAK2突变(OR=2.99,95%CI 1.07~8.42)、JAK3突变(OR=4.83,95%CI 1.50~15.60)及TEL-AML1融合基因(OR=0.43,95%CI 0.21~0.87)。

关键数值与推荐

  • 第19天MRD≥1.00%组114例、<1.00%组392例;第46天MRD≥0.01%组76例、<0.01%组430例。
  • PTPN11突变OR=1.92(95%CI 1.00~3.63)、KMT2A突变OR=3.51(95%CI 1.07~11.50)、年龄>10岁OR=1.91(95%CI 1.12~3.24)为第19天MRD≥1.00%的独立危险因素。
  • TEL-AML1融合基因OR=0.48(95%CI 0.27~0.87)、BCR-ABL1融合基因OR=0.27(95%CI 0.08~0.92)为第19天MRD≥1.00%的独立保护因素。
  • BCORL1突变OR=2.96(95%CI 1.18~7.44)、JAK2突变OR=2.99(95%CI 1.07~8.42)、JAK3突变OR=4.83(95%CI 1.50~15.60)为第46天MRD≥0.01%的独立危险因素;TEL-AML1融合基因OR=0.43(95%CI 0.21~0.87)为独立保护因素。

临床怎么用

  • 初诊B-ALL患儿应关注RAS信号通路及PTPN11、KMT2A、BCORL1、JAK2、JAK3等基因突变状态。
  • 携带PTPN11、KMT2A突变或年龄>10岁的患儿,第19天MRD≥1.00%风险较高,需加强早期MRD监测。
  • 携带BCORL1、JAK2、JAK3突变的患儿,第46天MRD≥0.01%风险较高,需关注后续MRD清除情况。
  • TEL-AML1或BCR-ABL1融合基因阳性的患儿MRD升高风险相对较低,但仍需按规范监测MRD。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To describe the gene mutation profile of newly diagnosed pediatric B-acute lymphoblastic leukemia (B-ALL) and analyze its effect on minimal residual disease (MRD). Methods: A total of 506 newly diagnosed B-ALL children treated in Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences from September 2018 to July 2021 were enrolled in this retrospective cohort study. The enrolled children were divided into MRD ≥1.00% group and <1.00% group according to MRD results on the 19th day since chemotherapy, and MRD ≥0.01% group and <0.01% group according to MRD results on the 46th day. Clinical characteristics and gene mutations of two groups were compared. Comparisons between groups were performed with chi-square test or Fisher's exact test. Independent risk factors of MRD results on the 19th day and the 46th day were analyzed by Logistic regression model. Results: Among all 506 patients, there were 318 males and 188 females. On the 19th day, there were 114 patients in the MRD ≥1.00% group and 392 patients in the MRD <1.00% group. On the 46th day, there were 76 patients in the MRD ≥0.01% group and 430 patients in the MRD <0.01% group. A total of 187 gene mutations were detected in 487 (96.2%) of 506 children. The most common gene mutations were signal transduction-related KRAS gene mutations in 111 cases (22.8%) and NRAS gene mutations in 99 cases (20.3%). Multivariate analysis showed that PTPN11 (OR=1.92, 95%CI 1.00-3.63), KMT2A (OR=3.51, 95%CI 1.07-11.50) gene mutations and TEL-AML1 (OR=0.48, 95%CI 0.27-0.87), BCR-ABL1 (OR=0.27, 95%CI 0.08-0.92) fusion genes and age >10 years (OR=1.91, 95%CI 1.12-3.24) were independent influencing factors for MRD ≥1.00% on the 19th day. BCORL1 (OR=2.96, 95%CI 1.18-7.44), JAK2 (OR=2.99, 95%CI 1.07-8.42) and JAK3 (OR=4.83, 95%CI 1.50-15.60) gene mutations and TEL-AML1 (OR=0.43, 95%CI 0.21-0.87) fusion gene were independent influencing factors for MRD ≥0.01% on the 46th day. Conclusions: Children with B-ALL are prone to genetic mutations, with abnormalities in the RAS signaling pathway being the most common. Signal transduction related PTPN11, JAK2 and JAK3 gene mutations, epigenetic related KMT2A gene mutation and transcription factor related BCORL1 gene mutation are independent risk factors for MRD. 目的: 描述初诊急性B淋巴细胞白血病(B-ALL)患儿基因突变谱并分析其对微小残留病(MRD)的影响。 方法: 回顾性队列研究。选取2018年9月至2021年7月中国医学科学院血液病医院诊治的506例初诊B-ALL患儿为研究对象。入组患儿依据化疗开始第19天MRD结果分为MRD≥1.00%组和<1.00%组,依据第46天MRD结果分为MRD≥0.01%组和<0.01%组。分别比较不同组患儿临床特征及基因突变等的差异,组间比较采用χ2检验或 Fisher 确切概率法。通过Logistic回归分析第19天和第46天MRD的独立影响因素。 结果: 506患儿中男318例、女188例。第19天MRD≥1.00%组患儿114例、MRD<1.00%组患儿392例;第46天MRD≥0.01%组患儿76例、MRD<0.01%组患儿430例。506例患儿中487例(96.2%)患儿检测到共187种基因突变,其中信号转导相关KRAS基因(111例,占22.8%)、NRAS基因(99例,占20.3%)是常见的突变基因。多因素分析示PTPN11(OR=1.92,95%CI 1.00~3.63)、KMT2A(OR=3.51,95%CI 1.07~11.50)基因突变和TEL-AML1(OR=0.48,95%CI 0.27~0.87)、BCR-ABL1(OR=0.27,95%CI 0.08~0.92)融合基因及发病年龄>10岁(OR=1.91,95%CI 1.12~3.24)均为第19天MRD≥1.00%的独立影响因素。BCORL1(OR=2.96,95%CI 1.18~7.44)、JAK2(OR=2.99,95%CI 1.07~8.42)和 JAK3(OR=4.83,95%CI 1.50~15.60)基因突变及TEL-AML1融合基因(OR=0.43,95%CI 0.21~0.87)均是第46天MRD≥0.01%的独立影响因素。 结论: 儿童B-ALL易发生基因突变,以RAS信号通路异常最常见。信号转导相关PTPN11、JAK2、JAK3基因突变,表观遗传相关KMT2A基因突变,转录因子相关BCORL1基因突变是MRD的独立危险因素。.

来源:Zhonghua Er Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. Gao YY, Jia YJ, Qi BQ, et al. [Genomics of next generation sequencing in pediatric B-acute lymphoblastic leukemia and its impact on minimal residual disease]. Zhonghua Er Ke Za Zhi. 2023. PMID: 37312464. doi:10.3760/cma.j.cn112140-20230417-00278

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。